Surprising Variability in Tryptamine Profiles of Psilocybe cubensis Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions
Amiel Sharchaton, Shilat Parsha, Sara P. Azerrad, Yaron Dekel, Nisreen Rabah, Tomáš Páleníček, Eyal Kurzbaum
Journal of Fungi July 2, 2026 Peer reviewed DOI: 10.3390/jof12070486 via OpenAlex
Summary
Psilocybin levels in 14 strains of Psilocybe cubensis varied significantly, with total tryptamine concentrations differing by over 7.8-fold, ranging from 2.62 to 20.65 mg/g. Psilocybin was the most prevalent compound, but there was also notable variability within individual strains, with psilocybin coefficients of variation between 12.81% and 23.39%. This highlights challenges in standardizing mushroom preparations for research or therapeutic use.
Study at a glance
| Sample size | 14 |
|---|---|
| Population | 14 distinct strains of Psilocybe cubensis mushrooms |
| Key finding | Total tryptamine concentrations varied by more than 7.8-fold among strains, underscoring significant biochemical diversity. |
Abstract
Psilocybin-producing mushrooms exhibit considerable biochemical diversity, yet the extent of variability among strains within a single species under standardized conditions remains insufficiently characterized. In this study, we quantified psilocybin, psilocin, baeocystin, norbaeocystin, aeruginascin, and norpsilocin in the fruiting bodies of 14 distinct strains of Psilocybe cubensis. The mushroom strains were cultivated, dried, extracted, and analyzed under uniform laboratory conditions. Despite strict methodological standardization, total tryptamine concentrations varied by more than 7.8-fold among strains (from 2.62 to 20.65 mg/g), with psilocybin consistently emerging as the dominant compound. Analysis of individual fruiting bodies within the selected strains revealed substantial intra-strain variability, with coefficients of variation for psilocybin ranging from 12.81% to 23.39% between individual fruiting bodies. These findings demonstrate that both inter- and intra-strain biochemical heterogeneity persist even under controlled conditions, underscoring the challenges of standardizing whole mushroom preparations for research or therapeutic use. Our results highlight the importance of strain selection, rigorous chemical profiling, and dosing precision in future pharmacological and clinical applications of P. cubensis.